openPR Logo
Press release

Primary Sclerosing Cholangitis Market Growth, Demand and Forecast Till 2023 Explore By Global Players Allergan Plc., Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc.

02-28-2019 06:35 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Global Primary Sclerosing Cholangitis Market

Global Primary Sclerosing Cholangitis Market

Primary sclerosing cholangitis market report provides detailed information about various candidates that are presently in the preclinical and clinical trials by the manufacturers and research organizations. The drug segment will provide quick snapshot about the clinical phase of the study, study outcomes, estimated launch date, and the upcoming drug molecules. Moreover, the report entails information regarding the major events taking place in the global market, thereby gaining insights about drug approvals, merger agreements, and acquisitions undertaken by the manufacturing companies. Also, incidence and prevalence of PSC and its associated conditions at regional as well as global level are provided in the report, thereby indicating the total number of addressable patient pool in the respective regions and market opportunity for the same.

Ask For In-depth Sample Copy of This Report @ https://bit.ly/2EjNoOm

Market Dynamics

Major factors that are expected to augment growth of the primary sclerosing cholangitis market include increasing number of organizations focusing on clinical innovation and scientific progress on understanding the mechanisms and risk factors for primary sclerosing cholangitis (PSC). For instance, the International PSC study group (IPSCSG), founded in 2010, aims to coordinate PSC research projects between leading institutions worldwide, thereby allowing feasible translational research and advancing efficient research. Also, increasing number of clinical and preclinical trials conducted by the research universities and pharmaceuticals companies is expected to favor market growth over the forecast period.

Global Primary Sclerosing Cholangitis Market- Optimistic Regional Scenario:

Currently, over five products are in clinical trials Phase 2 and some of them have shown good results in Phase 2. For instance, ASEOP trial, testing Obeticholic acid (OCA) for primary sclerosing cholangitis, is being conducted by Intercept Pharmaceuticals, Inc. Also, Shire Plc. completed Phase 2 clinical trial for the drug candidate LUM001 in February, 2016. If these potential molecules pass through the advanced clinical trials phase (i.e. Phase 3) and secure regulatory approval, these would be among the first-to-get-approval for this disease.

Moreover, most of the patients are in developed economies such as Europe and North America where diagnosis percentage and affordability is generally higher compared to emerging economies in regions such as Asia Pacific, which would result in higher adoption rate of novel products with significantly high yearly cost (i.e. more than US$ 50,000 for orphan drugs). Due to the above mentioned factors, the global primary sclerosing cholangitis market is expected to reach US$ 140.4 Mn by 2023. However, withdrawal of potential therapeutic molecules from late-stage clinical trials have limited the availability of efficient treatment, thus compelling the patient pool to adopt alternative treatment therapies such as bile acid sequestrants, antibiotics, antihistamines, opioid antagonists, and ursodeoxycholic acid (UDCA).

Increasing incidence of liver failure and bile cancer associated with PSC

Increasing prevalence of diseases associated with PSC such as liver cancer and inflammatory bowel disease is expected to enhance the therapeutic adoption of efficient drugs to manage the condition, thus driving growth of the primary sclerosing cholangitis market. According to the World Journal of Gastroenterology, 2017, inflammatory bowel disease (IBD) is diagnosed in around 50-80% of the patients with PSC, with ulcerative colitis (UC) comprising around 80-90% of these cases.

Primary Sclerosing Cholangitis Market - Competitive Analysis

Major players operating in the global primary sclerosing cholangitis market include

1. Acorda Therapeutics, Inc.
2. Gilead Sciences, Inc.
3. NGM Biopharmaceuticals, Inc.
4. Intercept Pharmaceuticals, Inc.
5. Dr. Falk Pharma GmbH
6. Allergan Plc.
7. Shire Plc.
8. Durect Corporation
9. Conatus Pharmaceuticals, Inc.
10. Sirnaomics, Inc.
11. Shenzhen HighTide Biopharmaceutical Ltd.

Primary Sclerosing Cholangitis Market - Taxonomy

By Drug: BTT1023, GS-9674, NGM282, OCA, Cenicriviroc, LUM001, DUR928, norUDCA, HTD1801, IDN-7314, STP705
By Region: North America, Latin America, Europe, Asia Pacific, Middle East, Africa

Browse Complete Research Report @ https://bit.ly/2EAyO6n

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Sclerosing Cholangitis Market Growth, Demand and Forecast Till 2023 Explore By Global Players Allergan Plc., Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc. here

News-ID: 1622460 • Views:

More Releases from Coherent Market Insights

Global Antihistamine Drugs Market Expected to Expand at a Steady 2024-2031 | Bayer AG, Almirall  S.A, GlaxoSmithKline, Johnson and Johnson.
Global Antihistamine Drugs Market Expected to Expand at a Steady 2024-2031 | Bay …
Coherent Market Insights introduces new research on the Global Antihistamine Drugs Market covering the micro level of analysis by competitors and key business segments (2024-2031). This report study encompasses a thorough examination of diverse segments, including opportunities, size, development, innovation, sales, and overall growth trajectory of major players. The research is carried out on primary and secondary statistical sources, providing a blend of qualitative and quantitative insights. The report also
Incretin Mimetics Market Future Business Opportunities 2024-2031 | GSK, Novo Nordisk, Lily, Haosoh, Sanofi, AstraZeneca, Pfizer Inc.
Incretin Mimetics Market Future Business Opportunities 2024-2031 | GSK, Novo Nor …
Coherent Market Insights introduces new research on the Incretin Mimetics Market covering the micro level of analysis by competitors and key business segments (2024-2031). This report study encompasses a thorough examination of diverse segments, including opportunities, size, development, innovation, sales, and overall growth trajectory of major players. The research is carried out on primary and secondary statistical sources, providing a blend of qualitative and quantitative insights. The report also focuses
Skin Rash Treatment Market Huge Growth in Future Scope 2024-2031 | AbbVie, Amgen, Bristol Myers Squibb, Galderma, Johnson & Johnson.
Skin Rash Treatment Market Huge Growth in Future Scope 2024-2031 | AbbVie, Amgen …
Coherent Market Insights introduces new research on the Skin Rash Treatment Market covering the micro level of analysis by competitors and key business segments (2024-2031). This report study encompasses a thorough examination of diverse segments, including opportunities, size, development, innovation, sales, and overall growth trajectory of major players. The research is carried out on primary and secondary statistical sources, providing a blend of qualitative and quantitative insights. The report also
Global Vitamin API Market Growth in Future Scope 2024-2031 | DSM, BASF, BOC Sciences, CSPC Pharmaceutical Group Limited.
Global Vitamin API Market Growth in Future Scope 2024-2031 | DSM, BASF, BOC Scie …
Coherent Market Insights introduces new research on the Global Vitamin API Market covering the micro level of analysis by competitors and key business segments (2024-2031). This report study encompasses a thorough examination of diverse segments, including opportunities, size, development, innovation, sales, and overall growth trajectory of major players. The research is carried out on primary and secondary statistical sources, providing a blend of qualitative and quantitative insights. The report also

All 5 Releases


More Releases for Primary

Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
Global Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis report offers insights into vital aspects like growth,CAGR value, market share and revenue analysis. It evaluates the growth opportunities, threats, market drivers and risks involved. understand the market competition by analyzing the top vendors, with their market profile, revenue, profits, import-export details, and market share. it states the pricing structure, import-export details, supply chain analysis, SWOT analysis to facilitate the key decision-making process. This report helps
Primary Lithium Battery (Primary Lithium Batteries) Industry Analysis by 2025:  …
In its recently published report, QY Research has provided unique insights about global Primary Lithium Battery (Primary Lithium Batteries) market for the given period. One of the main objectives of this report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the global Primary
Primary Cells And Primary Batteries Market Analysis by Production Capacity, Dyna …
This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Primary Cells And Primary Batteries market. Description The Global Primary Cells And Primary Batteries Market report offers a comprehensive evaluation of the Global Primary Cells And Primary Batteries industry. This report evaluates the Global market for " Global Primary Cells And Primary Batteries". The Global Primary Cells
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
01-25-2017 | Health & Medicine
TMR
Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Inciden …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes